When it comes to approving new medical treatments the Food and Drug Administration is balancing the need for patient safety against the urgency of making important new treatments available as quickly as possible Some argue the FDA sets the bar too high requiring a process that takes too much time and money to carry out They say that can leave patients waiting longer than necessary for promising treatments or lead to drugs not being developed at all But others counter that letting drugs on the market before its known whether they truly help or hurt patients is a serious risk They argue that the FDA actually has a high rate of approving new drugs  and that in critical cases that process can be accelerated A team of experts recently faced off two against two for an   debate on the motion The FDAs Caution Is Hazardous to Our Health Before the debate the audience voted  percent in favor of the motion with  percent against and  percent undecided After the debate  percent agreed The FDAs Caution Is Hazardous to Our Health while only  percent disagreed  making the side arguing in favor of the motion the winners of the debate  MD is a practicing physician and a resident fellow at the American Enterprise Institute From  Gottlieb served as deputy commissioner at the Food and Drug Administration and before that from  as a senior adviser to FDA Commissioner Mark McClellan and as the FDAs director of medical policy development He left the FDA in the spring of  to work on implementation of the new Medicare drug benefit as a senior adviser to the administrator of Medicare and Medicaid Services where he supported the agencys policy work on quality improvement and coverage and payment decisionmaking particularly as it related to new medical technologies Gottlieb has held editorial positions on the   and the   and appears regularly as a guest commentator on the cable financial news channel CNBC  is a senior fellow at the Manhattan Institute writing on the issues of drug development energy technology and the law Before joining the Manhattan Institute Huber served as an assistant and later associate professor at the Massachusetts Institute of Technology for six years He clerked on the DC Circuit Court of Appeals for Ruth Bader Ginsburg and then on the US Supreme Court for Sandra Day OConnor Huber also is a partner at the Washington DC law firm of Kellogg Huber Hansen and Todd He is the author of    which he cowrote with Mark P Mills He is also author of the forthcoming book    MD is a professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Womens Hospital An internist geriatrician and drug epidemiologist he studies the intended and adverse effects of prescription drugs physician prescribing practices and medication policy Avorn pioneered the academic detailing approach to continuing medical education in which noncommercial evidencebased information about drugs is provided to doctors through educational outreach programs run by publicsector sponsors Such programs are now in use in the US Canada Australia and Europe He has served as a member of the Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines and is the author or coauthor of more than  papers in the medical literature on medication use and its outcomes He is the author of the book     MD is vice president emeritus for health affairs of the University of Florida Challoner has held leadership and health policy positions in many national organizations including the Association of American Medical Colleges where he holds distinguished service membership the American Medical Association where he served as chairman of the Section on Medical Schools and the American Federation for Clinical Research where he served as president From  he was appointed by President Reagan to chair the Presidents Committee on the National Medal of Science He also served as a member of the governing council of the Institute of Medicine and was a member of the governing board of the National Research Council He received the  Walsh McDermott Medal of the IOM for distinguished service He chaired the IOMs Committee on the Public Health Effectiveness of the FDA K Clearance Process 